Literature DB >> 12270738

Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8.

Shigeto Yamamoto1, Hirohisa Yano, Osamu Sanou, Hakuo Ikegami, Masashi Kurimoto, Masamichi Kojiro.   

Abstract

We have studied the antiviral activities of five recombinant interferon-alpha (IFN-alpha) subtypes, namely IFN-alpha1, -alpha2, -alpha5, -alpha8 and -alpha10, in eight human liver cancer cell lines. The relative antiviral activities, expressed in terms of the mean 50% inhibitory concentration (IC50), were different for each cell line. In general, IFN-alpha8 was the most potent, IFN-alpha2, -alpha5, and -alpha10 were intermediately active, and IFN-alpha1 was the least potent in the all cell lines. The observed differences between the IC50s of IFN-alpha1 and -alpha8 ranged from 250- to 2200-fold in these cell lines. Thus, the ranking order of relative antiviral activity was similar but the sensitivity to the subtypes was different among these cell lines. The relative antiviral activities of the subtypes were associated with the induction of 2',5'-oligoadenylate synthetase (2',5'-OAS) in the typical hepatocellular carcinoma cell line HAK-3 but not in the cell line KYN-3. Next, we examined for synergistic antiviral activity induced by IFN-alpha2 and -alpha8 that has been reported for the hepatocellular carcinoma cell line, HepG2. Synergism was observed in three of the eight liver cell lines at an IFN-alpha2 to -alpha8 ratio of 60:40, and is considered to reflect the synergistic induction of 2',5'-OAS.

Entities:  

Year:  2002        PMID: 12270738     DOI: 10.1016/s1386-6346(02)00020-7

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.

Authors:  Toshio Ariyasu; Takeshi Tanaka; Noboru Fujioka; Yoshiaki Yanai; Shigeto Yamamoto; Hiroshi Yamauchi; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jan-Feb       Impact factor: 2.416

2.  Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.

Authors:  Catherine François; Isabelle Bernard; Sandrine Castelain; Bryan Charleston; Martin D Fray; Jean-Claude Capiod; Gilles Duverlie
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.

Authors:  Amy Thomas; Carl Laxton; Joanne Rodman; Nisha Myangar; Nigel Horscroft; Tanya Parkinson
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

4.  The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types.

Authors:  Herwig P Moll; Thomas Maier; Anna Zommer; Thomas Lavoie; Christine Brostjan
Journal:  Cytokine       Date:  2010-10-12       Impact factor: 3.861

5.  Enhanced anti-HCV activity of interferon alpha 17 subtype.

Authors:  Aurelie Dubois; Catherine François; Veronique Descamps; Carole Fournier; Czeslaw Wychowski; Jean Dubuisson; Sandrine Castelain; Gilles Duverlie
Journal:  Virol J       Date:  2009-06-03       Impact factor: 4.099

6.  Different antiviral effects of IFNα subtypes in a mouse model of HBV infection.

Authors:  Jingjiao Song; Sheng Li; Yun Zhou; Jia Liu; Sandra Francois; Mengji Lu; Dongliang Yang; Ulf Dittmer; Kathrin Sutter
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

7.  IFITM1 is a tight junction protein that inhibits hepatitis C virus entry.

Authors:  Courtney Wilkins; Jessica Woodward; Daryl T-Y Lau; Amy Barnes; Michael Joyce; Nicola McFarlane; Jane A McKeating; D Lorne Tyrrell; Michael Gale
Journal:  Hepatology       Date:  2012-12-12       Impact factor: 17.425

8.  Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

Authors:  Woubalem Birmachu; Raymond M Gleason; Barbara J Bulbulian; Christie L Riter; John P Vasilakos; Kenneth E Lipson; Yuri Nikolsky
Journal:  BMC Immunol       Date:  2007-10-12       Impact factor: 3.615

9.  Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms.

Authors:  Michael S Harper; Kejun Guo; Kathrin Gibbert; Eric J Lee; Stephanie M Dillon; Bradley S Barrett; Martin D McCarter; Kim J Hasenkrug; Ulf Dittmer; Cara C Wilson; Mario L Santiago
Journal:  PLoS Pathog       Date:  2015-11-03       Impact factor: 6.823

10.  Severe acute respiratory syndrome coronavirus elicits a weak interferon response compared to traditional interferon-inducing viruses.

Authors:  Carolina Scagnolari; Simona Trombetti; Simona Cicetti; Silvia Antonelli; Carla Selvaggi; Lorena Perrone; Michela Visca; Sara Romano; Guido Antonelli
Journal:  Intervirology       Date:  2008-09-10       Impact factor: 1.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.